Souhaitez-vous accéder aux communiqués récents ?

New York, USA, July 08, 2025 (GLOBE NEWSWIRE) -- Alzheimer’s Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances |...

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today...

Longeveron CEO Wa’el Hashad will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.

Toronto, Ontario, June 04, 2025 (GLOBE NEWSWIRE) -- LifeLabs, a leading provider of health diagnostics and laboratory services, is proud to announce the launch of a comprehensive portfolio of...

Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory.Improves Memory and Behavior:...

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.

Inflammasome-driven microglial inflammation key to accumulation of toxic phosphorylated alpha-synuclein leading to neurodegeneration and Parkinson's.

Longeveron selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.